From ARR to EBITDA: The Next Discipline for Healthcare Startup Founders

For many healthcare startup founders, the journey from Seed to Series A is defined by one primary objective: prove that the business can grow. Growth, typically measured through Annual Recurring Revenue (ARR), becomes the central narrative. It signals product-market fit, validates demand, and demonstrates the potential for scale in a complex and highly regulated industry. Investors lean into this metric because, at the earliest stages, growth is the clearest indicator that a company is building something customers actually want.

But as companies mature, even slightly beyond Series A, the conversation often begins to change. It does not happen all at once. There is no single board meeting where expectations suddenly shift. Instead, it is subtle. Questions evolve. The tone changes. And gradually, the focus moves from growth alone to something more demanding: the quality and durability of that growth, and ultimately, the path to sustainable EBITDA.

Why ARR Dominates Early

In the early stages of a healthcare startup, EBITDA is often a poor reflection of business health. Founders are investing aggressively in product development, clinical validation, go-to-market teams, and integrations with systems like EHRs or payer infrastructure. Losses are expected, and in many cases, encouraged.

ARR, on the other hand, offers a cleaner signal. It represents contracted, repeatable revenue. Whether it is a per-member-per-month contract with a payer, a SaaS subscription with a provider group, or a per-episode fee model in a health setting, for example, ARR tells investors that the revenue engine is beginning to take shape. It also allows for comparisons across companies using metrics like growth rate, retention, and expansion.

In U.S. healthcare, where reimbursement complexity is influenced by organizations like the Centers for Medicare & Medicaid Services, ARR can often feel more stable than EBITDA. Timing differences in claims, denials, and collections can distort profitability, making EBITDA less useful as a decision-making tool in the early innings.

The Inflection Point: When EBITDA Starts to Matter

As your company grows, however, ARR is no longer enough. At some point-typically post-Series A or heading into Series B-investors begin to ask a different set of questions:

• Is this revenue repeatable?
• How much does it cost to generate and support it?
• Does it translate into actual cash flow?
• What happens if growth slows?

This is where the concept of the EBITDA bridge becomes more important. An EBITDA bridge is simply a structured way of explaining how you move from reported profitability to adjusted profitability, often by adding back “one-time” or non-recurring costs. Early on, these adjustments are accepted with relatively little friction. Founders might add back implementation costs, clinical hiring ramp, or integration expenses, and investors will largely accept the rationale.

But over time, tolerance for these adjustments declines. What was once viewed as “one-time” begins to look recurring. What was once a clean story begins to look more like financial engineering. The bridge itself does not disappear-but every step on it is scrutinized more carefully.

The Subtle Shift from Story to System

The most important transition founders need to understand is this: The conversation moves from believing your story to trusting your system. In the Seed stage, a compelling narrative can carry significant weight. If you can articulate a large market, a differentiated solution, and early traction, investors are willing to take a leap of faith.

By the time you reach growth stage, that leap is no longer sufficient. Investors want evidence that your performance is structurally repeatable. They begin to look beyond individual quarters and ask whether the business is built to sustain its results over time.

This shift often manifests in subtle ways:

• More detailed follow-up questions in board meetings
• Increased focus on cash flow rather than adjusted EBITDA
• Reduced tolerance for add-backs and adjustments
• Greater scrutiny from lenders and capital partners

None of this means something is wrong. It simply means the bar has moved.

Why This Is Harder in Healthcare?

Healthcare startups face unique challenges in making this transition.

First, revenue is often “noisy.” Payment cycles can stretch 60 to 120 days or longer. Claims can be denied and resubmitted. Value-based care models may introduce performance-based payments that are episodic or delayed. All of this creates variability that can make EBITDA appear inconsistent.

Second, cost structures are complex. Clinical staffing, compliance requirements, and integration costs can fluctuate as the business scales. What appears to be a one-time investment often recurs in different forms as new customers are onboarded.

Third, regulatory and reimbursement dynamics can change. A shift in policy from the Centers for Medicare & Medicaid Services or a major payer can impact both revenue and margins, sometimes with little notice.

These factors make it tempting to rely heavily on adjusted metrics and narrative explanations. But as scrutiny increases, those explanations must give way to operational discipline.

What Investors Are Really Asking

At its core, the question investors are trying to answer is simple: Is this business built to endure?

They are not just evaluating whether you can grow. They are evaluating whether you can grow efficiently and sustainably. This is why EBITDA begins to matter more. Not because profitability is the immediate goal, but because it reflects the underlying economics of the business. It forces a closer look at how revenue translates into margin, and how margin translates into cash.

Building Toward Sustainable EBITDA

For founders navigating this transition, the goal is not to optimize EBITDA overnight. It is to demonstrate a credible path toward it, supported by real operational improvements.

There are four areas that matter most:

1. Repeatable Revenue: Focus on building revenue streams that are predictable and durable. This might mean longer-term contracts, stronger retention, or deeper integration into customer workflows. In healthcare, this often involves embedding your solution into clinical or operational processes that are difficult to replace.

2. Clean Financials: Reduce reliance on aggressive add-backs. Be transparent about costs and how they scale. Investors do not expect perfection, but they do expect clarity. A simpler, cleaner EBITDA bridge builds more trust than a complex one.

3. Cash Discipline: Pay close attention to cash flow. Improve collections, manage working capital, and understand the timing of your revenue. In healthcare, revenue cycle management can be just as important as revenue generation.

4. Operational Rigor: Develop processes that scale. This includes standardized onboarding, consistent service delivery, and clear unit economics. Whether your metric is cost per patient, per episode, or per member per month, you need to understand it deeply and improve it over time.

The New Narrative

Ultimately, the narrative you present to investors must evolve.

Early on, the story is about possibility:

• The size of the market
• The uniqueness of the solution
• The speed of growth

Later, the story becomes about durability:

• The consistency of performance
• The efficiency of operations
• The reliability of cash generation

Both narratives matter. But they serve different purposes at different stages.

Final Thought

Every healthcare startup that succeeds at scale goes through this transition. Some recognize it early and adapt. Others are caught off guard, wondering why investor sentiment has shifted even as revenue continues to grow.

The reality is that growth alone is not enough. At some point, every company must prove that it is not just growing, but built to sustain that growth.

In simple terms: ARR gets you noticed. EBITDA, and the discipline behind it, earns long-term trust.

For founders who have raised a Seed or Series A round, the next phase is not about abandoning growth. It is about strengthening the foundation beneath it, so that when scrutiny increases, as it inevitably will, you are ready not just with a compelling story, but with a business that truly holds up.

The article was written with AI assistance by Jon Warner, Executive Chair of Dealstream and Decision-support Architect for Innovation, Technology, Digital Health, and Aging populations, where a ‘System 2’ Mgt thinking approach is critical